Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: PrimeraDx Gets Medical Device Manufacturing Certification


PrimeraDx said this week that it has received certification for ISO 13485:2003, an International Organization for Standardization medical device quality management standard.

BSI Group America performed the review according to ISO 13485:2003 requirements, and focused on PrimeraDx’s design, manufacturing, and distribution of multiplex instrumentation and assays for molecular diagnostics.

Based in Mansfield, Mass., PrimeraDx has developed a technology called scalable target amplification routine, or STAR, which integrates standard endpoint PCR with capillary electrophoresis to simultaneously and quantitatively measure multiple target nucleic acids.

The company has also developed an integrated, benchtop instrument platform called ICEPlex to run STAR-based assays on up to 96 samples simultaneously, including controls, and report on up to 60 targets in each sample in less than four hours (PCR Insider, 7/14/2011).

PrimeraDx currently offers ICEPlex as an open platform to laboratories wishing to develop their own molecular diagnostic tests.

"Achieving ISO 13485:2003 certification is an important milestone and distinguishing differentiator for PrimeraDx. It demonstrates to our customers, collaborators, and companion diagnostic partners that we are dedicated to quality at every level of the organization,” CEO and President Matt McManus said in a statement.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.